Korean AI-driven drug developers seek expansion in overseas markets

KOREA – Korean AI-driven drug developers are establishing overseas branches or a wet lab to seek new business opportunities. Several AI-backed drug discovery companies have emerged in Korea to find new medicines. Standigm, Syntekabio, Deargen, Oncocross, Pharos iBio, Baobab AiBIO, PharmCADD, and AZothBio are among them. Cimplrx announced a joint development and licensing agreement with Dong-A ST in September to develop an innovative drug for central nervous system diseases, piqued the interest of the pharmaceutical industry. In addition, some AI-driven new drug developers have established a web lab, progressing to…

Read More